1. Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma. (December 2016) Authors: Berdeja, J.G.; Lin, Y.; Raje, N.; Siegel, D.; Munshi, N.; Turka, A.; Lam, L.P.; Quigley, M.T.; Kochenderfer, J.N. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). (April 2017) Authors: Savona, M.R.; Garcia-Manero, G.; Roboz, G.J.; Walsh, K.J.; Kropf, P.L.; Issa, J.P.; O'Connell, C.L.; Tibes, R.; Yee, K.W.L.; Stock, W.; Lunin, S.; Berdeja, J.G.; Naim, S.; Hao, Y.; Azab, M.; Kantarjian, H. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗